Apimeds Pharmaceuticals US, Inc. — Form 8-K Summary
Business Context and Reporting Period
The filing reports corporate charter amendments and a reverse stock split. The reported event date is July 24, 2026, with the reverse stock split effective at 12:01 a.m. Eastern Time on that date. The company is incorporated in Delaware, trades on the NYSE American under the symbol APUS, and qualifies as an emerging growth company.
Financial Metrics and Capital Structure
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
- Before the split, 15,091,180 shares of common stock were issued and outstanding.
- Following the split, 1,509,118 shares were issued and outstanding, before an additional 33,506 shares were issued to address fractional-share rounding through the Depository Trust Company.
- Authorized capital remained unchanged at 100,000,000 common shares and 10,000,000 preferred shares.
- The common stock par value decreased from $0.01 to $0.001 per share.
Material Changes Versus the Prior Comparable Period
- The company implemented a one-for-ten reverse stock split: every ten shares were combined into one share.
- No fractional shares were issued; holders otherwise entitled to fractional shares received one whole share.
- Outstanding equity awards and warrants, including their underlying share amounts and exercise prices, were adjusted proportionately.
- The stock began trading on a split-adjusted basis at the open of trading on July 24, 2026.
- The company received stockholder approval by written consent on December 1, 2025, and subsequently filed the charter amendment with Delaware on July 23, 2026.
- The post-split common stock CUSIP is 03771D201.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing provides no financial guidance or management outlook. The principal unusual item is the reverse stock split and related share-count, equity-award, warrant, par-value, and trading adjustments. Investors should consider potential effects on market liquidity, share price, dilution calculations, and warrant and equity-award terms. The filing text does not identify additional contingencies or operating risks.
Key Facts Investors Should Verify
- Confirm the effective date and one-for-ten ratio of the reverse stock split.
- Verify the final post-split share count, including the additional 33,506 shares issued for fractional-share rounding.
- Review the full Certificate of Amendment for the precise legal terms.
- Confirm that equity awards and warrants were adjusted consistently with the reverse split.
- Check subsequent SEC filings for updated capitalization, financial results, liquidity, and any effects on NYSE American listing compliance.
- Note that the supplied text contains a chronology inconsistency: although the report concerns July 24, 2026, it is signed September 22, 2026, and references an exhibit incorporated from a Form 10-Q filed August 14, 2026.